FULC Q1 2024 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$479,000

Operating Income

-$30M

Net Income

-$27M

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$233M

Total Liabilities

$19M

Stockholders' Equity

$214M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$295,000	-100.0%
Gross Profit	-$479,000	-$16M	+97.1%
Operating Income	-$30M	-$28M	-6.8%
Net Income	-$27M	-$25M	-8.4%